A phase Ib study of BEZ235, a dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), in patients with advanced renal cell carcinoma

Oncologist

Volumn 21, Issue 7, 2016, Pages 787-788

  Carlo, Maria I ^a   Molina, Ana M ^b   Lakhman, Yulia ^a   Patil, Sujata ^a   Woo, Kaitlin ^a   Deluca, John ^a   Lee, Achung Han ^a   Hsieh, James J ^a   Feldman, Darren R ^a   Motzer, Robert J ^a   Vossa, Martin H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACTOLISIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; QUINOLINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; FATIGUE; HUMAN; HYPERLIPASEMIA; HYPERTRANSAMINASEMIA; HYPERURICEMIA; KIDNEY CARCINOMA; MACULOPAPULAR RASH; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; THORAX PAIN; TREATMENT RESPONSE; TUMOR GROWTH; VOMITING; AGED; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; CLINICAL TRIAL; FEMALE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMIDAZOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASE; QUINOLINES; TOR SERINE-THREONINE KINASES;

EID: 84978708621     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2016-0145     Document Type: Article

References (0)